Similar articles

• Response to Kourtis et al. 'Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis'.

  Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Townsend CL, et al. AIDS. 2007 Aug 20;21(13):1831-2. doi: 10.1097/QAD.0b013e3282748e97. AIDS. 2007. PMID: 17690590 No abstract available.
• Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis.

  Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Kourtis AP, et al. AIDS. 2007 Mar 12;21(5):607-15. doi: 10.1097/QAD.0b013e32802ef2f6. AIDS. 2007. PMID: 17314523 Review.
• Antiretroviral Therapy and Adverse Pregnancy Outcome: The Elephant in the Room?

  Mofenson LM. Mofenson LM. J Infect Dis. 2016 Apr 1;213(7):1051-4. doi: 10.1093/infdis/jiv390. Epub 2015 Aug 10. J Infect Dis. 2016. PMID: 26265779 No abstract available.
• The safety of highly active antiretroviral therapy for the HIV-positive pregnant mother and her baby: is 'the more the merrier'?

  Martin F, Taylor GP. Martin F, et al. J Antimicrob Chemother. 2009 Nov;64(5):895-900. doi: 10.1093/jac/dkp303. Epub 2009 Aug 25. J Antimicrob Chemother. 2009. PMID: 19706669 Review.
• Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-to-child transmission.

  Short CE, Douglas M, Smith JH, Taylor GP. Short CE, et al. HIV Med. 2014 Apr;15(4):233-8. doi: 10.1111/hiv.12083. Epub 2013 Sep 11. HIV Med. 2014. PMID: 24025074